While the selective serotonin-reuptake inhibitors (SSRIs) are the first line treatment for juvenile depression and anxiety disorders, other novel antidepressants not chemically related to the SSRIs have also been prescribed to children and adolescents for unlabeled (non-FDA-approved) indications. These medications include bupropion, (Wellbutrin™), duloxetine Hydrochloride (Cymbalta™), mirtazapine (Remeron ™), trazodone (Desyrel™), venlafaxine (Effexor ™) and desvenlafaxine (Pristiq™). Their psychopharmacological profile and relevant pediatric studies are summarized in this chapter. Alternative or complimentary treatments (e.g. St. John's Wort, Omega-3 fatty acids, thyroid hormones, and S-Adenosyl Methionine (SAMe)) are also reviewed.
|Original language||English (US)|
|Title of host publication||Pharmacotherapy of Child and Adolescent Psychiatric Disorders: Third Edition|
|Publisher||John Wiley and Sons|
|Number of pages||25|
|State||Published - Feb 17 2012|
- Pediatric Psychopharmacology
ASJC Scopus subject areas